IDH2 and glioblastoma: Interestingly, IDH1 and IDH2 mutated GBM, SDHB deficient pheochromocytoma and paraganglioma are more sensitive to temozolomide (TMZ), and IDH1/2 mutations are con-sidered a good prognostic factor.